Main Renal Artery Plus Branch Ablation in the Treatment of Resistant Hypertension with Renal Denervation
Methods: Sixty patients with resistant hypertension were enrolled. The patients were randomly assigned to the main renal artery plus branch ablation group or the main renal artery ablation group. The clinical data and operation-related parameters, including number of ablation points, temperature, and average energy, were recorded. Ambulatory blood pressure was taken for all patients at the baseline and at 6 months after treatment. Office blood pressure was recorded before treatment and after treatment every 3 months for 2 years.
Results: Sixty patients with resistant hypertension were enrolled in this study. There were 30 patients in each group. Angiography was performed after ablation. No renal artery complications, such as stenosis and dissection, occurred in the two groups. There was no significant difference in age, sex, BMI, comorbid disease, and medication between the two groups (P>0.05). The number of ablation points for the main renal artery plus branch ablation group was greater than that for the main renal artery ablation group. The office blood pressure and 24-hour blood pressure were significantly lower 6 months after treatment than before treatment in both groups (P<0.05). Office blood pressure in the main renal artery plus branch ablation group was lower than that in the main renal artery ablation group during the 3‐12-month follow-up period, with a statistical difference. However, as the follow-up time increased, the difference disappeared.
Conclusion: The results of this study show that main renal artery plus branch ablation is a safe interventional method, but there was no obvious advantage on long-term follow-up compared with only main renal artery ablation.
Document Type: Research Article
Affiliations: Department of Cardiology, Putuo Center Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 200062 Shanghai, People’s Republic of China
Publication date: December 1, 2021
This article was made available online on October 1, 2021 as a Fast Track article with title: "Main Renal Artery Plus Branch Ablation in the Treatment of Resistant Hypertension with Renal Denervation".
Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. Cardiovascular Innovations and Applications is the official journal of the Great Wall International Congress of Cardiology (GW-ICC). It aims to continue the work of the GW-ICC by providing a global scientific communication platform for cardiologists that bridges East and West.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites